A, Incidence of postmarket boxed warnings or withdrawals issued by year (1996-2013). B, Incidence of premarket boxed warnings by approval year (1996-2012).
eTable 1. Premarket and Postmarket Boxed Warnings for New Drug Approvals, 1996-2012
eTable 2. Market Withdrawals of Novel Therapeutic Drugs, 1996-2013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Cheng CM, Shin J, Guglielmo BJ. Trends in Boxed Warnings and Withdrawals for Novel Therapeutic Drugs, 1996 Through 2012. JAMA Intern Med. 2014;174(10):1704–1705. doi:10.1001/jamainternmed.2014.4854
Boxed warnings describe potentially life-threatening risks associated with certain prescription drugs.1 The warnings are surrounded by a border or “box” in the drug label and may be present at the time of drug approval (ie, a premarket warning) or added during the postmarket period (ie, a postmarket warning). Despite the use of boxed warnings for the most serious adverse reactions, trends and associated predictors for such warnings have not been well characterized. The objective of this study was to determine the frequency of premarket and postmarket boxed warnings and safety-related withdrawals for novel therapeutics approved between 1996 and 2012.
Institutional review board approval was waived by the University of California, San Francisco, Committee on Human Research. All drug labeling histories, boxed-warning-related safety announcements, and safety-related withdrawals associated with novel therapeutics (ie, new pharmacological or biological molecular entities) approved between 1996 and 2012 were reviewed. Primary data sources were the Center for Drugs Evaluation and Research (CDER) and Medwatch websites2,3; the Physicians’ Desk Reference was used for historic labels unavailable online. Approval date, presence or absence of a premarket warning, and date of US Food and Drug Administration (FDA) communications issued between 1996 and 2013 for a safety-related withdrawal or addition of new safety risks to a boxed warning were recorded. Median times to first postmarket boxed warning or withdrawal based on presence or absence of a premarket boxed warning were calculated and compared using the Wilcoxon rank sum test. Descriptive statistics were used to examine patterns in drug type (pharmacological or biological) and approval year (before or after 2004, the study midpoint). Multiple logistic regression analyses were used to estimate the likelihood of a boxed warning based on drug type and approval year. We used SAS version 9.3 (SAS Institute Inc) for statistical analyses, and P < .05 was considered statistically significant.
There were 522 novel therapeutics approved during our study, including 441 pharmacological and 81 biological products. One hundred eighty had ever received a boxed warning (136 pharmacological and 44 biological products); 105 had only received premarket warnings, 50 only acquired postmarket warnings, and 25 had both (eTable 1 in the Supplement). In total, there were 89 postmarket boxed warnings, and 11 withdrawals (eTable 2 in the Supplement), most of which (81%) occurred after 2004 (Figure, A).
Premarket warnings were more common among biological than pharmacological products (31% vs 22%, respectively; odds ratio, 2.0, 95% CI, 1.2-3.3) and among drugs approved after 2004 compared with drugs approved earlier (36% vs 18%, respectively; odds ratio, 2.4; 95% CI, 1.6-3.6) (Figure, B).
Median time from approval to first postmarket boxed warning or withdrawal was 4.2 years (range, 0.2-15.2 years) and was shorter for drugs with premarket warnings (2.3 years; range, 0.2-11.8 years) than drugs without premarket warnings (4.9 years; range, 0.2-15.2 years) (P < .001).
Our study demonstrates that boxed warnings are common, affecting more than one-third of recent drug approvals. While nearly three-quarters of boxed warnings had been applied to novel therapeutics at the time of approval, more than 40% acquired the warning after a median market period of 4 years. Not surprisingly, the frequency of boxed warnings increased in the post-2004 period, which coincided with the aftermath of the rofecoxib (Vioxx, Merck) withdrawal and subsequent launch of FDA initiatives to strengthen drug safety surveillance, particularly postmarket reporting.4,5 Our finding that half of biological products had boxed warnings is consistent with literature suggesting that biological products pose greater risks of serious adverse events compared with other drug types.6 It should be noted, however, that our study was limited in sample size and excluded biological products under jurisdiction of the Center for Biologics Research and Evaluation. Furthermore, our study included only CDER-regulated drugs and therefore was not a comprehensive review of all drugs approved since 1996. Clinicians should be aware of the prevalence and growing numbers of boxed warnings and the importance of continued adverse event reporting for identifying new safety concerns.
Corresponding Author: Christine M. Cheng, PharmD, Disease Decision Support Group, First Databank Inc, 701 Gateway Blvd, Ste 600, South San Francisco, CA 94080 (email@example.com).
Published Online: August 15, 2014. doi:10.1001/jamainternmed.2014.4854.
Author Contributions: Drs Cheng and Shin had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Cheng, Shin.
Drafting of the manuscript: Cheng.
Critical revision of the manuscript for important intellectual content: Shin, Guglielmo.
Statistical analysis: Cheng, Shin.
Administrative, technical, or material support: Guglielmo.
Study supervision: Cheng, Guglielmo.
Conflict of Interest Disclosures: Dr Cheng is employed by First Databank Inc, a commercial drug knowledge vendor. No other disclosures are reported.
Correction: This article was corrected on August 25, 2014, to revise a table entry in eTable 1 in the Supplement.
Create a personal account or sign in to: